THE FUTURE IS NOW WITH
ASPIRADOME™
RED BLOOD CELL REDUCTION 🩸
Minimizing red blood cell contamination in PRP formulations enhances treatment by reducing the potential for inflammation and oxidative stress. In leukocyte-poor PRP, less than 1% RBC content creates a clean, regenerative environment ideal for healing soft tissue and joints, while in monocyte-rich PRP, keeping RBCs low helps preserve the therapeutic benefits of modulated inflammation. This level of purity ensures greater biologic precision, improved cellular viability, and more consistent clinical outcomes.